Farms.com Home   News

Boissevain beekeeper hoping to bounce back

A Boissevain-area beekeeper says conditions are improving.

Don Glover lost all of his 100 hives last fall because of the Varroa mite.

However, losing his bees last fall did allow him to regroup for this year.

"There were some big losses with big beekeepers too. It wasn't a good year. Last year for us here was about the best honey crop we've ever had and that was kind of the frustrating part because the best honey crop we ever had and you end up with your bees all dead."

He adds this spring was less than ideal for the new bees he had ordered last fall.

"It's been terrible, it's too cold. The dampness doesn't matter so much but there was a lot of cold days. That was a double whammy because the bees we had left, we had a tough, tough, time to get them going. This time of year, the bees are weaker than what they should be by this time of year but then the crops, they're just planting canola right now. We're maybe ok if we get some good weather, we could still pull off a pretty good crop."

Glover has been in the honey business for more than 30 years.

Click here to see more...

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.